Supporting R&D decision-making for over 20 of the top global biopharma companies
Data sourced at the point of care
Thousands of oncology clinicians rely on Flatiron HCTM every day. These partnerships form the foundation for consistent data.
Learn more about Flatiron HCTM
Regulatory experience across the U.S., Europe, and Asia
Working with our biopharma partners, we have supported multiple briefing packages. Our data have also been incorporated in submissions to the FDA, EMA, and PMDA.
Subscribe to our regulatory intel newsletter
Tumor-specific and tumor-agnostic datasets with real-world outcomes
Our data models across more than 20 tumor types for clinical and clinico-genomic datasets include rigorously assessed real-world mortality, progression, and response outcome variables.
Learn more about our data products
Fit-for-purpose analytical tools
With a toolkit and guidance tailored for Flatiron data, our data scientists and industry peers are working together to achieve efficient and transparent insight generation with reproducible analytical results.
Learn more about the Flatiron R Universe
Specialized expertise along every stage of our data pipeline
Our oncologists, quantitative scientists, regulatory affairs experts, HTA program teams, and more than 1,000 clinically trained abstractors work together to deliver top-quality data.
Meet Flatiron's leadership team
Flatiron RWD featured in more than 350 peer-reviewed publications
We advance clinical research with our research partners and publish the findings to share our progress and learnings.
View our publications
Advancing the use of RWE with our research collaborators
Flatiron RWD has been used in projects across the drug development life cycle
Discovery & early development
Our RWD demonstrated that STK11 and KEAP1 mutations are negatively associated with real-world outcomes in both chemotherapy and PD-1/PD-L1 checkpoint inhibitors-treated NSCLC patients.
Our RWD can help inform the design of randomized controlled trials, such as by informing the selection of inclusion/exclusion criteria.
To inform regulatory decision making, RWD needs to be fit-for-purpose and tailored to specific regulatory and clinical contexts. Our RWD has provided supportive evidence to inform regulatory decision making.
Our RWD was used to help assess the safety of a drug in breast cancer patients with a certain type of heart failure, leading to a favorable label update in Europe and the U.S.
HTA bodies around the world assessed our RWD to characterize the natural history of a disease as part of reimbursement evaluations for novel therapies.
Real-World Evidence Library
Your destination for the latest thought leadership on real world data uses, applications and case studies.
More than 20 of the world’s top biopharma companies use Flatiron real-world data products to support their R&D pipelines and enhance their understanding of real-world cancer care.
Our foundational datasets, covering more than 20 tumor types, reflect cancer patients’ journeys from diagnosis to treatment and real-world outcomes.
These growing datasets link Foundation Medicine’s genomic profiling data with Flatiron’s EHR-derived clinical and outcomes data for disease-specific and disease-agnostic analyses.
Customized projects that include one-time data delivery and expert analytic, regulatory and HTA support tailored to answer a specific research question.
Add-ons to our products:
Real-world outcome variables
Flatiron’s real-world outcome variables, used to derive real-world endpoints, account for the inherent complexities of patient outcomes specific to each cancer type.